CORRELATION BETWEEN SERUM LEVEL GALECTIN-3 AND EARLY REMODELLING INDICATOR OF LEFT VENTRICLE IN PATIENT WITH ACUTE MYOCARDIAL INFARCTION DURING PRE-PERCUTANEOUS CORONARY INTERVENTION
Abstract
Background: Coronary heart disease (CHD) is a leading cause of death worldwide. Acute coronary syndrome (ACS) is a spectrum of CHD. Left ventricle remodelling is one of the complication with the bad outcome either short-term or long term. Early remodelling process (within 0-72 hours) post infarction can be assessed by circulating biomarker (Galectin-3), echocardiography, coronary angiography, and clinically.
Objective: The aim of study is to know the correlation between serum level of Galectin-3 and early remodelling indicator in patient with acute myocardial infarction during pre-percutaneous coronary intervention. The parameters are LVEDV, LVEF, diastolic function component, TIMI flow, MBG, and presence of acute heart failure.
Materials and Methods: This cross sectional study was conducted in Sanglah General Hospital during March-May 2018. A 62 sample was determined consecutively.
Results: Bivariate analysis with Spearman correlation shows Galectin-3 correlated with LVEDV (r = 0,808; p= 0,000), E/e’ average (r = 0,297; p = 0,019), E/A ratio (r = 0,261; p= 0,041), and MBG (QuBE) (r = 0,647; p = 0,000). No correlation was found between Galectin-3 and LVEF Teich (r = -0,213; p= 0,097), LVEF Biplane (r = -0,226; p = 0,077), LAVI (r = 0,301; p = 0,170), e’septal (r = -0,079; p = 0,539), e’lateral (r = -0,092; p = 0,476), and TR Vmax (r=0,068; p=0,600). Chi square analysis shows no association between Galectin-3 and diastolic dysfunction left ventricle (OR= 1,032, p= 0,966, CI95%= 0,239-4,462), TIMI flow (OR= 1,032, p= 0,966, CI95%= 0,239-4,462), MBG score (OR= 0,264, p= 0,197, CI95%= 0,031-2,259), and acute heart failure (OR=0,577, p= 0,476, CI95%= 0,127-2,617). Multivariat analysis with multiple linear regression shows an increase in Galectin-3 has been proven associated independently with LVEDV, LAVI, E/e’ average, and E/A ratio. Multiple logistic regression shows Galectin-3 has not been proven independently with diastolic dysfunction, TIMI flow, MBG score, and acute heart failure. LVEDV is the best outcome that can be explained as its value influenced by constant, BMI, and Galectin-3 (R2 = 0,509).
Conclusion: Galectin-3 correlated with LVEDV, average E/e’, E/A ratio, and MBG (QuBE). There is an independent association between Galectin-3 and LVEDV, LAVI, average E/e, and E/A ratio. Early remodelling process within 0-72 hours post infarction was happened pre-PCI. Anti-remodelling (including anti failure) during early phase is strongly recommended in order to prevent worse outcome in short and long term.
Keywords: Galectin-3, early remodelling left ventricle, acute myocardial infarction, percutaneous coronary intervention.
Downloads
References
2017. Acute myocardial infarction. The Lancet,
389(10065), pp.197-210.
2. Meijers, W.C., van der Velde, A.R., Pascual-Figal,
D.A. and de Boer, R.A., 2015. Galectin-3 and postmyocardial
infarction cardiac remodeling. European
journal of pharmacology, 763, pp.115-121.
3. Bivona, G., Bellia, C., Sasso, B.L., Agnello, L.,
Scazzone, C., Novo, G. and Ciaccio, M., 2016.
Short-term Changes in Gal 3 Circulating Levels
After Acute Myocardial Infarction. Archives of
Medical Research, 47(7), pp.521-525.
4. Tsays, T.H., Sung, P.H., Chang, L.T., Sun, C.K.,
Yeh, K.H., Chung, S.Y., Chua, S., Chen, Y.L., Wu,
C.J., Chang, H.W. and Ko, S.F., 2012. Value and
level of Galectin-3 in acute myocardial infarction
patients undergoing primary percutaneous coronary
intervention. Journal of atherosclerosis and thrombosis,
19(12), pp.1073-1082.
5. Ibanez, B., James, S., Agewall, S., Antunes, M.J.,
Bucciarelli-Ducci, C., Bueno, H., Caforio, A.L.,
Crea, F., Goudevenos, J.A., Halvorsen, S. and
Hindricks, G., 2017. 2017 ESC Guidelines for
the management of acute myocardial infarction in
patients presenting with ST-segment elevation: The
Task Force for the management of acute myocardial
infarction in patients presenting with ST-segment
elevation of the European Society of Cardiology
(ESC). European heart journal, 39(2), pp.119-177.
6. Zornoff, L.A., Skali, H., Pfeffer, M.A., Sutton,
M.S.J., Rouleau, J.L., Lamas, G.A., Plappert,
T., Rouleau, J.R., Moyé, L.A., Lewis, S.J. and
Braunwald, E., 2002. Right ventricular dysfunction
and risk of heart failure and mortality after
myocardial infarction. Journal of the American
College of Cardiology, 39(9), pp.1450-1455.
7. Gibson, C. M., & Schömig, A. (2004). Coronary
and myocardial angiography: angiographic
assessment of both epicardial and myocardial
perfusion. Circulation, 109(25), 3096-3105.
8. Frunza, O., Russo, I., Saxena, A., Shinde, A. V.,
Humeres, C., Hanif, W., ... & Frangogiannis,
N. G. (2016). Myocardial galectin-3 expression
is associated with remodeling of the pressureoverloaded
heart and may delay the hypertrophic
response without affecting survival, dysfunction,
and cardiac fibrosis. The American journal of
pathology, 186(5), 1114-1127.
9. Sanchiz-Gomar, F., Perez-Quilis, C., Leischik, R.
and Lucia, A., 2016. Epidemiology of coronary
heart disease and acute coronary syndrome. Annals
of translational medicine, 4(13).
10. Weir, R. A., Petrie, C. J., Murphy, C. A., Clements,
S., Steedman, T., Miller, A. M., & McMurray, J.
J. (2013). Galectin-3 and Cardiac Function in
Survivors of Acute Myocardial InfarctionClinical
Perspective. Circulation: Heart Failure, 6(3), 492-
498.
11. Gaborit, F., Bosselmann, H., Kistorp, C., Iversen,
K., Kumler, T., Gustafsson, F., & Schou, M. (2016).
Galectin 3: association to neurohumoral activity,
echocardiographic parameters and renal function in
outpatients with heart failure. BMC cardiovascular
disorders, 16(1), 117.
12. Hamdy, R., Mohamed, L., Abdel-Rahman, T., El-
Malah, A., & Abd-Allah, M. (2014). Clinical and
Echocardiographic Correlation of Galectin-3 in
Well Defined Heart Failure Patients. AAMJ, 12
PDF downloads: 2468
Copyright (c) 2019 Indonesian Journal of Cardiology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
